On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Pure Extract Poised to Benefit as Mainstream Society Embraces Functional Mushrooms

  • Following $1.25 million donation, UC Berkeley launching Center for the Science of Psychedelics
  • Pure Extract Technologies Inc. expanding into functional and medicinal mushroom market
  • Psychedelic compounds increasingly being studied to treat wide range of physical, mental conditions
  • Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell, functional mushroom products

For hundreds of years, medicinal mushrooms have been revered among both ancient and modern cultures throughout the world for their nutritional and medicinal qualities. Pure Extract Technologies, a private plant-based Canadian extraction company headquartered in British Columbia, is leveraging the latest in science in its goal to become the leading extraction company engaged in the development and commercialization of functional and medicinal products.

Psychedelics appear to be going mainstream, as evidenced by the planned launch of the UC Berkeley Center for the Science of Psychedelics following an anonymous donation of $1.25 million for startup costs. Last studied over 50 years ago, UC Berkeley is once again opening the doors to psychedelic research with an aim to study the possible medical benefits of psychedelic drugs, specifically the chemical compound psilocybin found in “magic” mushrooms.

“There’s never been a better time to start a center like this,” said UC Berkeley neuroscientist and co-founder David Presti. “The renewal of basic and clinical science with psychedelics has catalyzed interest among many people.”

Psychedelic compounds are increasingly being researched for possible benefits that include anti-tumor effects, improved immune function, anti-viral properties, mental wellness benefits and detoxification. Specific neurochemical-related conditions of particular interest to leading academic and medical research institutions include depression, anxiety, PTSD, obesity, narcolepsy, bipolar disorder, Alzheimer’s, OCD, ADHD and drug and alcohol addiction.

Psychedelics were granted FDA breakthrough therapy status for treatment-resistant depression in 2020 with approvals expected in 2021.

Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell and produce functional mushroom products in an EU-GMP-compliant environment, adequately positioning the Company to partner with organizations that plan to develop both functional and psychedelic products. Further solidifying the Company’s position on a global scale is its 10,000 square foot facility designed for EU-GMP certification that will enable sales throughout the world.

In addition to functional and medicinal products, Pure Extracts’ business model consists of three other verticals in connection with its existing cannabis and hemp extraction business. They include the marketing of in-house brands; toll processing – services in connection with the conversion of raw biomass into extracted oil products; and white labeling – the supply of products to existing brands looking to sell edibles, custom formulated oils and other cannabis-related products.

With a top spot among the fastest growing industries in North America, the mushroom industry is currently in a transitory phase whereby dry biomass is being converted to extracts. With a strong position in the industry, Pure Extracts is poised to benefit from this emerging trend as mushroom based products continue to enter mainstream awareness, bolstered by scientific research and ages-old therapeutic use.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217